[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @AscendingBio AscendingBio AscendingBio posts on X about $pdsb, just a, future, $kura the most. They currently have XXX followers and XX posts still getting attention that total X engagements in the last XX hours. ### Engagements: X [#](/creator/twitter::1883175331747479552/interactions)  - X Week XXXXX -XX% - X Month XXXXXX -XX% - X Months XXXXXXX +78% ### Mentions: X [#](/creator/twitter::1883175331747479552/posts_active)  - X Week XX -XX% - X Month XX +9.60% - X Months XXX +110% ### Followers: XXX [#](/creator/twitter::1883175331747479552/followers)  - X Week XXX +5.80% - X Month XXX +12% - X Months XXX +150% ### CreatorRank: undefined [#](/creator/twitter::1883175331747479552/influencer_rank)  ### Social Influence **Social category influence** [finance](/list/finance) XXXX% **Social topic influence** [$pdsb](/topic/$pdsb) 4.17%, [just a](/topic/just-a) 4.17%, [future](/topic/future) 4.17%, [$kura](/topic/$kura) 4.17%, [market cap](/topic/market-cap) 4.17%, [$4151t](/topic/$4151t) 4.17%, [$2503t](/topic/$2503t) 4.17%, [money](/topic/money) 4.17%, [target](/topic/target) 4.17%, [investment](/topic/investment) XXXX% **Top accounts mentioned or mentioned by** [@stephanklingel1](/creator/undefined) [@kellymetz2000](/creator/undefined) [@sammy191189](/creator/undefined) [@nxus9488676607](/creator/undefined) [@mamdouhameen90](/creator/undefined) [@notechnicals](/creator/undefined) [@chris83489710](/creator/undefined) [@ddlow](/creator/undefined) ### Top Social Posts Top posts by engagements in the last XX hours "$PDSB Phase X likely to resume in January after December FDA meetings and receipt of minutes in January. The meeting minutes in this FDA context is not just a transcript of what transpired at the meeting. The key part of this document is the written FDA response to future actions. My understanding is that the FDA provides some response during these meetings but the answer that really matters is the one that is delivered in writing weeks later" [X Link](https://x.com/AscendingBio/status/1995859595508568285) 2025-12-02T14:16Z XXX followers, XXX engagements "$KURA Cash vs. Market Cap At last quarterly reported $XXXXX million in cash. Today announced a $XXX million payment from Kyowa Kirin. Market Cap is about XXX million" [X Link](https://x.com/AscendingBio/status/1995921283691810829) 2025-12-02T18:21Z XXX followers, XXX engagements "I am generally positive. There is a good chance this drug works well and ultimately is approved. Yet they have to look outside the company for money to move this forward. That can bring delays and significant problems. It is a buyout target. Yes there are positives here but also possible significant downsides. I typically keep my investment in a stock like this quite modest until there is more clarity about this future. I do this while watching closely for a signal to jump in with a larger investment" [X Link](https://x.com/AscendingBio/status/1996581924022657323) 2025-12-04T14:06Z XXX followers, XX engagements "That is a fair point. Thanks for expressing it. I certainly support ethical pricing. A reasonable price is especially important for those who do not have insurance. At this time ARS (Neffy) is not making a profit with their current pricing and roughly X% market share. That is why I grant them a little flexibility on initial pricing. Another factor is that with Anaphylm many will not engage in the practice of purchasing a set for home and and set for work (school). That should reduce some of the cost burden. A longer shelf life than EpiPen should also be helpful" [X Link](https://x.com/AscendingBio/status/1996938871683064021) 2025-12-05T13:45Z XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@AscendingBio AscendingBio
AscendingBio posts on X about $pdsb, just a, future, $kura the most. They currently have XXX followers and XX posts still getting attention that total X engagements in the last XX hours.
Engagements: X #
- X Week XXXXX -XX%
- X Month XXXXXX -XX%
- X Months XXXXXXX +78%
Mentions: X #
- X Week XX -XX%
- X Month XX +9.60%
- X Months XXX +110%
Followers: XXX #
- X Week XXX +5.80%
- X Month XXX +12%
- X Months XXX +150%
CreatorRank: undefined #
Social Influence
Social category influence finance XXXX%
Social topic influence $pdsb 4.17%, just a 4.17%, future 4.17%, $kura 4.17%, market cap 4.17%, $4151t 4.17%, $2503t 4.17%, money 4.17%, target 4.17%, investment XXXX%
Top accounts mentioned or mentioned by @stephanklingel1 @kellymetz2000 @sammy191189 @nxus9488676607 @mamdouhameen90 @notechnicals @chris83489710 @ddlow
Top Social Posts
Top posts by engagements in the last XX hours
"$PDSB Phase X likely to resume in January after December FDA meetings and receipt of minutes in January. The meeting minutes in this FDA context is not just a transcript of what transpired at the meeting. The key part of this document is the written FDA response to future actions. My understanding is that the FDA provides some response during these meetings but the answer that really matters is the one that is delivered in writing weeks later"
X Link 2025-12-02T14:16Z XXX followers, XXX engagements
"$KURA Cash vs. Market Cap At last quarterly reported $XXXXX million in cash. Today announced a $XXX million payment from Kyowa Kirin. Market Cap is about XXX million"
X Link 2025-12-02T18:21Z XXX followers, XXX engagements
"I am generally positive. There is a good chance this drug works well and ultimately is approved. Yet they have to look outside the company for money to move this forward. That can bring delays and significant problems. It is a buyout target. Yes there are positives here but also possible significant downsides. I typically keep my investment in a stock like this quite modest until there is more clarity about this future. I do this while watching closely for a signal to jump in with a larger investment"
X Link 2025-12-04T14:06Z XXX followers, XX engagements
"That is a fair point. Thanks for expressing it. I certainly support ethical pricing. A reasonable price is especially important for those who do not have insurance. At this time ARS (Neffy) is not making a profit with their current pricing and roughly X% market share. That is why I grant them a little flexibility on initial pricing. Another factor is that with Anaphylm many will not engage in the practice of purchasing a set for home and and set for work (school). That should reduce some of the cost burden. A longer shelf life than EpiPen should also be helpful"
X Link 2025-12-05T13:45Z XXX followers, XX engagements